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ABSTRACT
Background: The Cochrane risk of bias tool is a
prominent instrument used to evaluate potential biases
in clinical trials. In three updates of our Cochrane
review on neuraminidase inhibitors, we assessed risk
of bias on the same trials using different levels of
detail: the trials in journal publications, in core reports,
and in full clinical study reports. Here we analyse
whether progressively greater amounts of information
and detail in full clinical study reports (including trial
protocols, statistical analysis plans, certificates of
analyses, individual participant data listings and
randomisation lists) affected our risk of bias
assessments.
Methods and findings: We used the Cochrane risk
of bias tool to assess and compare risk of bias in 14
oseltamivir trials (reported in 10 clinical study reports)
obtained from the European Medicines Agency (EMA)
and the manufacturer, Roche. With more detailed
information, reported in clinical study reports, no
previous assessment of ‘high’ risk of bias was
reclassified as ‘low’ or ‘unclear’ in the main analysis,
and over half (55%, 34/62) of the previous
assessments of ‘low’ risk of bias were reclassified as
‘high’. Most assessments of ‘unclear’ risk of bias
(67%, or 28/42) were reclassified as ‘high’ risk of bias
when our judgements were based on full clinical study
reports. The limits of our study were our relative
inexperience in dealing with large information sets,
sometimes subjective bias judgements and focus on
industry trials. Comparison with journal publications
was not possible because of the low number of trials
published.
Conclusions: We found that as information increased
in the document, this increased our assessment of
bias. This may mean that risk of bias has been
insufficiently assessed in Cochrane reviews based on
journal publications.
INTRODUCTION
The risk of bias tool in Cochrane reviews of
randomised trials is routinely used to assess
essential items pertaining to validity of trial
design such as random sequence generation,
allocation concealment, attrition and
performance biases. There are six standard
bias elements, each rated at a ‘high’, ‘low’ or
‘unclear’ risk of bias.
As Cochrane reviews are typically based on
synthesising studies based on reports pub-
lished in the scientific literature, the risk of
bias tool is traditionally applied to journal
publications. To the best of our knowledge,
the ways in which risk of bias judgements
change when they are based on more
detailed reports of trials, such as those con-
tained in clinical study reports, have not
been previously investigated.
Clinical study reports are considered the
most exhaustive summaries of randomised
controlled trials of pharmaceuticals. Clinical
study reports are highly structured and
detailed documents that follow an outline
format agreed between regulators and manu-
facturers in 1995, described in the ICH E3
Strengths and limitations of this study
▪ The availability of full clinical study reports
decreased the uncertainty of bias judgements
and allowed clearer judgements to be made.
▪ The availability of full clinical study reports
allows reviewers to follow consistency across
chapters and appendices, creating a need for far
more interaction with the text.
▪ Our relative inexperience in dealing with large
quantities of information and our lack of familiar-
ity with certain trial documents may limit our
ability to assess risk of bias in clinical study
reports.
▪ The current Cochrane risk of bias tool is not
adequate for the task as it does not reliably iden-
tify all types of important biases, and nor does it
organise and check the coherence of large
amounts of information. This may have impacted
our findings.
▪ The custom data extraction sheet we have devel-
oped is for use with clinical study reports, and
may not apply to non-industry trials where clin-
ical study reports usually do not exist.
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document.1 2 Recent transparency policies adopted by
the European Medicines Agency (EMA),3 as well as
announcements by some pharmaceutical companies to
make clinical study reports more readily available, 4 5
suggest that clinical study reports may increasingly be
incorporated into systematic reviews and other forms of
evidence synthesis.
Although there is some variation in the structure and
content of clinical study reports, they are usually com-
posed of a core report of the trial and appendices. A core
report (sections 1–15 of the ICH E3 document) is struc-
tured in the Introduction, Methods Results and
Discussion (IMRAD) style. The numerous appendices
(section 16 of ICH E3) contain important online supple-
mentary data needed to understand and interpret the
trial, its context and history.1 2 These appendices include
such documents as the trial protocol, protocol amend-
ments, statistical analysis plan, blank case report forms,
certificates of analysis, randomisation lists and consent
forms. For the purposes of this paper, the core report
plus all its appendices will be known as the full clinical
study report (see online supplementary appendix 1 for
the table of contents of a typical oseltamivir clinical study
report and http://dx.doi.org/10.5061/dryad.77471 for a
free download of all the clinical study reports used in our
review and featured in this paper. The core report was
known as Module 1 in oseltamivir clinical study reports,
and appendices were found in Modules 2–5). Core
reports and full clinical study reports theoretically can
help reduce uncertainty in judging risk of bias.
In 2012, we published an update of our Cochrane
review of neuraminidase inhibitors which included a total
of 32 oseltamivir trials.6 Unlike most Cochrane reviews,
this review was based only on core reports,6 and risk of
bias assessments were therefore based on each core
report. Subsequently, in 2013, we obtained full clinical
study reports from Roche and, as part of a further system-
atic review update, carried out new risk of bias assessments
of the same trials based on the full clinical study reports.
Our overall aim was to investigate whether the level of
detail contained in reports of trials affects judgements
about risk of bias. We planned to achieve this by comparing
documents which contain increasingly detailed information
on each trial included in our review, namely journal publi-
cations, core reports and full clinical study reports. As well
as using the standard Cochrane risk of bias tool, we devel-
oped an additional list of study elements that we wanted to
extract in order to allow improved assessments of each
trial’s design and conduct and facilitate the organisation of
large quantities of information now available to us.
In this report, we describe our use of these tools to
address three specific questions:
1. Do core reports change the risk of bias evaluation
compared to published papers?
2. Do full clinical study reports change the risk of bias
evaluation compared to core reports?
3. Do full clinical study reports change the risk of bias
evaluation compared to published papers?
METHODS
Ten core reports (M76001; NV16871; WV15670; WV15671;
WV15707; WV15730; WV15759/WV15871; WV15799;
WV15812/WV15872; WV15819/WV15876/WV15978) were
received in PDF files from Roche and EMA by 12 April
2011 (the date of time lock for our 2012 Cochrane
review).6 The reporting of more than one trial in the same
clinical study report was justified by Roche as a conse-
quence of lower than expected participant recruitment
due to low influenza circulation and consequently a need
to pool studies.
The current Cochrane risk of bias tool consists of six
domains; each may have more than one source of bias
application, depending on the subject matter.7 Our
applications were as follows: selection bias (random
sequence generation and allocation concealment), per-
formance bias (blinding of participants and personnel—
all outcomes), detection bias (blinding of outcome
assessment—all outcomes), attrition bias (influenza
symptoms, complications and harms outcome data),
reporting bias (selective reporting) and other bias. The
identification of sources of other bias was left at the
reviewers’ discretion.
Risk of bias assessments were performed following
Cochrane methods 7 and published in 2012.6 In that
review, risk of bias was assessed by an external reviewer
on the basis of data extracted from core reports.
After 12 April 2011, we obtained the appendices of
the clinical study reports included in our review. For
most of the clinical study reports we requested, EMA
had the protocol, protocol amendments, statistical ana-
lysis plan, blank case report forms and other appendices
contained in what Roche terms the second ‘module’ of
a full clinical study report (see online supplementary
appendix 1). However, EMA did not possess—and there-
fore could not provide us with—full clinical study
reports with the exception of trial WP16263.8 For
approximately 3 years, Roche had repeatedly refused
our requests for full clinical study reports.9
In April 2013 in the course of carrying out these new
extractions, Roche changed its policy on access to data
and pledged to share with us 77 full clinical study
reports (http://www.bmj.com/tamiflu/roche). Fifteen
clinical study reports containing 20 trials were included
in the analysis of our current review.10 As we were
already in possession of core reports and appendices
such as the protocol and statistical analysis plan for the
14 trials in this analysis, the additional data for other
clinical study reports provided by Roche do not concern
this paper. In the clinical study reports, Roche redacted
information that they judged to be of ‘legitimate com-
mercial interest’ or present a risk of trial participant rei-
dentification. The redactions did not impede our
analyses of risk of bias.
On the basis of our growing familiarity with clinical
study reports, we designed and piloted a data extraction
sheet to record how our understanding of the trials
changed in the light of the availability of the additional
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appendices. We realised that, in addition to the standard
Cochrane risk of bias elements, we needed to organise
the abundant material at our disposal and reconstruct a
timeline of the trials. We used the Cochrane risk of bias
tool 7 to appraise clinical study reports and a data extrac-
tion sheet for recording information relevant to this
appraisal. We added the following elements to our
extraction sheets: date of participant enrolment,
unblinding of the trial, protocol for which we had the
full text, protocol amendments, statistical analysis plan
for which we have the full text (and its amendments),
patient consent form, randomisation list and certificate
of analysis. Timeline reconstruction allowed us to con-
ceptualise the design and conduct of the trials and
appreciate their role in the trial programme with their
strengths and limitations. In addition, following a time-
line allows a judgement to be made on the integrity and
temporal sequence of the documents. The finalised
extraction sheet is in online supplementary appendix 2.
On the basis of access to the full clinical study reports,
we carried out our final assessment of risk of bias. These
were carried out by a single reviewer, checked by a
second with final consensus reached through a
face-to-face discussion among the entire group.
Since with full clinical study reports there should be no
ambiguity, we only allowed ‘low’ or ‘high’ risk of bias jud-
gements (ie, no ‘unclear’). We adopted the position that,
unlike a publication which may have page limits, there
was no reason why a full clinical study report should be
missing details necessary for a third party to judge risk of
bias. Therefore, when information that would have other-
wise allowed us to judge a risk of bias as either ‘low’ or
‘high’ was missing, this would automatically be cate-
gorised as ‘high’ risk of bias. This decision to eliminate
the ‘unclear’ option when assessing full clinical study
reports was made following an initial assessment of the
trials, which included ‘unclear’ judgements. On the basis
of an earlier peer review of this paper, which suggested
we analyse the data had we kept the ‘unclear’ category,
we also carried out this post hoc analysis.
To allow for a comparison of risk of bias judgements
based on published reports of trials and risk of bias judge-
ments based on clinical study reports (either core reports
alone or full clinical study reports), we used our previous
risk of bias judgements for the same trials in the relevant
Cochrane reviews that had been based on publications.11 12
The extraction and adjudication methods used were
the same as those used in our subsequent unified
Cochrane review.6 We used descriptive methods to
answer our three questions without the need for formal
statistical analysis.
Ethics approval and patient consent were not neces-
sary for this study.
RESULTS
We could only compare risk of bias assessments between
core reports and full clinical study reports for the
following 14 trials (reported in 10 clinical study reports):
M76001; NV16871; WV15670; WV1Z5671; WV15707;
WV15730; WV15759/WV15871; WV15799; WV15812/
WV15872; WV15819/WV15876/WV15978 (figure 1 and
table 1).
We could not carry out a comparison of risk of bias
judgements of journal publications with core reports or
full clinical study reports, because our assessments were
largely based on secondary publications (notably, the
Kaiser et al pooled analysis of 10 trials, 8 of which were
unpublished13) rather than primary publications of the
trials, and also utilised an outdated risk of bias tool.
Hence, there were too few studies (3) for which we had
distinct risk of bias judgements of primary journal publi-
cations (many studies for which we have clinical study
reports were and remain unpublished, eg, 8 of the 13
trials in adults). In addition, the current Cochrane risk
of bias tool was introduced after the production of our
review of published articles, making the comparison,
had we had the data to undertake it, more difficult to
interpret and possibly unfair.
For the comparison of core and full clinical study
reports, table 2 shows that no previous assessment of
‘high’ risk of bias was reclassified as ‘low’ or ‘unclear’ in
the presence of more detailed information. Previous
assessments of ‘low’ risk of bias were not uncommonly
reclassified as ‘high’ bias in the subsequent assessment.
While our assessments based on core reports were mostly
classified as ‘low risk of bias’, they were reclassified in the
opposite direction as ‘high’ risk of bias when our judge-
ments were based on full clinical study reports (table 2).
A spreadsheet recording all individual risk of bias judge-
ments is available online (see online supplemental file 1).
Had we kept the ‘unclear’ risk of bias judgement
option when assessing full clinical study reports, 10 we
would have had 64 ‘unclear’ judgements (see sensitivity
analysis in table 3). The breakdown of these 64 judge-
ments into the various attributes is:
▸ Attrition bias: symptoms (10); complications (9);
safety (15). These are unclear because we do not
know the impact of missing symptoms data, and the
reports contained unclear definitions for secondary
complications of influenza and a seemingly problem-
atic decision tool for the alternative designation of
events as either complications or harms, which we
called ‘compliharms’ in our Cochrane review.
▸ Other bias (13)—these are unclear due to the unknown
effect of the dehydrocholic acid included in the placebo
but are not included in the active treatment.
▸ Performance bias (6)—these are unclear due to
missing certificates of analysis describing the placebo
appearance.
▸ Selection bias (10)—these are unclear due to the
missing or unclear randomisation lists, meaning we
cannot confirm random sequence generation.
▸ Detection bias (1)—this is unclear due to the
unknown impact of different coloured placebo caps
on outcome assessment.
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See tables 3 and 4. Twenty-nine per cent of previously
certain judgements (ie, ‘high’ or ‘low’ risk of bias) based
on core reports became ‘unclear’ with full clinical study
reports.
An example of the kind of detail available in full clin-
ical study reports, and the importance of the trial time-
line in assessing the presence of bias, is the observation
that of the clinical study reports for the 14 trials, only 1
contained a protocol which predated the beginning of
participant enrolment, only 2 had statistical analysis
plans which clearly predated participants enrolment and
3 had clearly dated protocol amendments. No clinical
study report reported a clear date of unblinding.
Completed extraction sheets with risk of bias compari-
sons and rationales are available on request from the
corresponding author.
DISCUSSION
We used the Cochrane six-item risk of bias instrument to
assess bias from two different levels of detail of trial
reports. Owing to the unrestricted access to full clinical
study reports, we took the view that all information
needed to judge risk of bias for each of the six domains
of the Cochrane risk of bias should be present. When
the information was not available, we judged the corre-
sponding risk of bias element as being ‘high’.
Therefore, the availability of full clinical study reports
decreased the uncertainty and allowed clearer judge-
ments to be made. Risk of bias previously assessed as
‘unclear’ based on core reports became a more certain
‘low’ or ‘high’ risk of bias. When the information was
not available, our judgements changed because we
found gaps in the availability of information and incon-
sistent information. Whether the full study reports repre-
sent an exhaustive and coherent source of trial narrative
and data remain unclear.
Throughout our study, we were assessing two different
types of material within the clinical study reports: those
that were created or written prior to patient enrolment
(eg, trial protocols), and those written after (eg, core
reports).
This approach is not possible when assessing trials
reported in journal publications, in which articles neces-
sarily reflect post hoc reporting with a far more sparse
level of detail. We suggest that when bias is so limiting as
Figure 1 Flow chart.
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to make meta-analysis results unreliable, either it should
not be carried out or a prominent explanation of its
clear limitations should be included alongside the
meta-analysis. We found the Cochrane risk of bias tool to
be difficult to apply to clinical study reports. We think
this is not because the tool was constructed to assess
journal publications but, as with all list-like instruments,
its use lends itself to a checklist approach (in which each
design item is sought and, if found, eliminated from the
bias equation rather than with thought and consider-
ation). Similarly, the extraction sheet we assembled
needs to be applied with thought and consideration—an
approach that does not lend itself to reviewing under
time pressure. However, more focus should be devoted
to bias itself and its effects rather than theoretical risk of
bias. Many of the variables we found to be important
when assessing the trial (eg, date of trial protocol, date
of unblinding, date of participant enrolment) are simply
not captured in the risk of bias tool when used in a
routine way or to review publications. We were also often
unsure how to judge the risk of bias when bias itself can
actually or potentially be measured with reviewers’
access to full clinical study reports and individual partici-
pant data. If, for example, the original trial protocol is
available, one can judge whether reporting bias
occurred. Reviewers need not guess at bias (ie, make a
judgement of ‘risk’) but can judge bias directly.
However, even with individual participant data, some
forms of bias, such as attrition bias, may still be difficult
to quantify, and one can only judge the risk (ie, poten-
tial) of bias. Therefore, access to detailed information
and participant level data sometimes found in full clin-
ical study reports provides an opportunity to consider
both actual as well as risk of biases.
Box 1 shows examples of the types of information
found in clinical study reports that led to risk of bias
assessment changes. While the judgements of ‘low’ or
‘high’ risk of bias may imply certainty, particularly when
based on the reading of a full clinical study report, we
found ourselves often in lengthy debate and discussion
over the proper level of risk of bias before arriving at a
consensus. We found the risk of bias judgements them-
selves to carry a high level of subjectivity, in which differ-
ent judgements can be justified in different ways. The
real strength of the risk of bias tool appears not to be in
the final judgements it enables, but rather in the
process it helps facilitate: critical assessment of a clinical
trial.
Table 3 Change in overall (all elements) risk of bias
judgments for 15 core reports of oseltamivir trials
compared with full clinical study reports including unclear
assessments
Risk of bias,
core reports
Risk of bias, full clinical
study reports
High,
n (%)
Unclear,
n (%)
Low,
n (%)
Total,
n (%)
High 11 (8) 15 (12) 0 (0) 26 (20)
Unclear 1 (1) 27 (21) 14 (11) 42 (32)
Low 12 (9) 22 (17) 28 (22) 62 (48)
Total 24 (18) 64 (49) 42 (32) 130 (100)
Table 1 Risk of bias assessments performed by trial, 2009–2014
Trial (s)
Risk of bias assessment performed based on
Pooled analysis13
(2009 Cochrane
review22)
Journal publication
(2007, 2009 and
2010 Cochrane
reviews12 22 23)
Core report
(2012 Cochrane
review6)
Full clinical study report
(2014 Cochrane review10)
M76001 x x x
NV16871 x x
WV15670 x x x
WV15671 x x x
WV15707 x x x
WV15730 x x x
WV15759 WV15871 x x
WV15799 x x x
WV15812 WV15872 x x x
WV15819 WV15876
WV15978
x x x
Table 2 Change in overall (all elements) risk of bias
judgments for 15 core reports of oseltamivir trials
compared with full clinical study reports
Risk of
bias, core
reports
Risk of bias, full clinical
study reports
High,
n (%)
Unclear,
n (%)
Low,
n (%)
Total,
n (%)
High 26 (20) 0 (0) 0 (0) 26 (20)
Unclear 28 (22) 0 (0) 14 (11) 42 (32)
Low 34 (26) 0 (0) 28 (22) 62 (48)
Total 88 (68) 0 (0) 42 (32) 130 (100)
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Another aspect to emerge is that tools based on publi-
cations are designed to detect the presence, absence or
uncertainty regarding elements in a very restricted
number of places in the text. The availability of full clin-
ical study reports allows reviewers to follow consistency
across chapters and appendices, creating a need for far
more interaction with the text. An example of this active
engagement is the cross-checking of active principle and
placebo batches used across trials and their connection
with a visual description of their properties such as
colour in a certificate of analysis. For example, once the
presence of a differently coloured placebo capsule cap
in trial WP16263 was identified through the clinical
study report’s certificate of analysis, its potential impact
on blinding was captured in the Cochrane instrument.
The interpretation of such a finding is difficult, as the
colours of the active principle and placebo capsule caps
are close (ivory and light yellow). However, publication-
based or core report only based assessments would not
have identified the potential differences in colour as the
descriptions are simply given as ‘placebo’14 and ‘match-
ing placebo’,15 respectively. Reviewing the complete clin-
ical study reports and our assessment of bias was very
time consuming, necessitating prolonged exchanges
including a face-to face meeting given the novelty of
what we were doing. However, this activity was not as dif-
ficult or as time consuming as the reconstruction of trial
evidence programmes for oseltamivir, an activity which
necessitated a whole time equivalent researcher for
6 months. However, owing to the threat of reporting
bias, we can think of no alternative to the use of full clin-
ical study reports.
The main limitation of our study is our relative inex-
perience in dealing with large quantities of information
and our lack of familiarity with certain trial documents
such as randomisation lists. Randomisation lists
appeared to be of two types. The first was a prerandomi-
sation list of random codes with which participants’ IDs
cannot be matched with the participant IDs used within
other sections of the clinical study report. The second
was a post hoc randomisation list to which individual
participants can be matched, but the original generated
codes are not shown. In both cases, the truly random
generation of the sequence could not be properly
assessed because either the original codes are not pro-
vided or they cannot be matched to patients. Another
limitation of our study is that the instrument we have
developed is for using with clinical study reports, and
may not apply to non-industry trials (which may not
have a clinical study report).
The background to our use of clinical study reports
was our mistrust of journal publications of oseltamivir
trials. Many trials were unpublished, and of those pub-
lished, we found and documented examples of
Table 4 Change in overall (all elements) risk of bias judgments for 15 full clinical study reports reports of oseltamivir trials
with and without allowing unclear assessments
Risk of bias, full
clinical study reports
Risk of bias, full clinical study reports allowing unclear
assessments
High, n (%) Unclear, n (%) Low, n (%) Total, n (%)
High 24 (18) 64 (49) 0 (0) 88 (68)
Unclear 0 (0) 0 (0) 0 (0) 0 (0)
Low 0 (0) 0 (0) 42 (32) 42 (32)
Total 24 (18) 64 (49) 42 (32) 130 (100)
Box 1 Examples of risk of bias assessment changes and
other concerns
▸ In trial WV15708, the risk of bias related to allocation conceal-
ment went from ‘Unclear’ based on core reports to ‘High’ risk
of bias based on full clinical study reports because the full
clinical study report did not report sufficient details about the
method of allocation concealment.
▸ In trial WV15707, the risk of bias related to random sequence
generation went from ‘Unclear’ based on core reports to ‘High’
risk of bias based on full clinical study reports because a full
description of the randomisation procedure was not provided.
▸ Prophylaxis trials WV15673 and WV15697 are described as
‘identical’, but this could not be verified as we had only one
protocol (and the protocol we did have was dated after the
study’s completion). In addition, the placebo event rates for
influenza infection were very different between the two trials
and their pooling, combined with the redaction of centre
numbers, preventing from them being individually added to a
meta-analysis. Therefore, our assessment of the ‘Other’ risk of
bias item changed from ‘unclear’ based on core reports to
‘high’ based on full clinical study reports.
▸ In the treatment trials WV15819, WV15876 and WV15978, it
was difficult to reconcile the total number of hospitalisations
despite access to the full clinical study reports. One patient in
the placebo arm who was hospitalised according to serious
adverse event narratives does not appear in the hospitalisa-
tions table, and for a separate placebo patient who is listed in
the serious adverse event narratives, no hospitalisation is
described in this narrative, but the same patient was hospita-
lised according to the hospitalisations table. It was therefore
unclear how many hospitalisations occurred in the trial, to
whom and why.
▸ In prophylaxis trials WV15673 and WV15697, bias was
assessed as low for selective reporting because the
intention-to-treat population was described and reported in a
table. However, when the full clinical study report became
available, we realised that the original protocol was missing.
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reporting bias. At least one trial publication was drafted
by an unnamed medical writer. As evidence of reporting
bias in industry trial publication mounts, 8 16–21 we
believe Cochrane reviews should increasingly rely on
clinical study reports as the basic unit of analysis.
Sponsors and researchers both have a responsibility to
make all efforts to make full clinical study reports pub-
licly available. The systematic evaluation of bias or risk of
bias remains an essential aspect of evidence synthesis, as
it forces reviewers to critically examine trials. However,
the current Cochrane risk of bias tool does not suffi-
ciently identify possible faults with study design, and nor
does it help to organise and check the coherence of
large amounts of information that are found in clinical
study reports. Our experience suggests that more
detailed extraction sheets that prompt reviewers to con-
sider additional aspects of study may be needed. Until a
more appropriate guide is developed, we offer our
custom extraction sheets to Cochrane reviewers and
others interested in assessing risk of bias using clinical
study reports and encourage further development.
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